This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Humana (HUM) Q1 Earnings Beat on Solid Healthcare Services
by Zacks Equity Research
Humana (HUM) still has $2 billion remaining under its share repurchase authorization.
FibroGen (FGEN) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
FibroGen (FGEN) delivered earnings and revenue surprises of -113.24% and 62.59%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Aclaris Therapeutics (ACRS) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Aclaris (ACRS) delivered earnings and revenue surprises of -2.78% and 16.98%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate FibroGen (FGEN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
FibroGen (FGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FibroGen (FGEN) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
FibroGen (FGEN) delivered earnings and revenue surprises of 500.00% and 15.25%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Perrigo (PRGO) This Earnings Season?
by Zacks Equity Research
Perrigo's (PRGO) new products as well as products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.
FibroGen (FGEN) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
FibroGen (FGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Organogenesis (ORGO) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
On Organogenesis' (ORGO) upcoming third-quarter earnings call, investor focus is likely to be on the sales performance of its two segments - advanced wound care, and surgical & sports medicine.
Can FibroGen (FGEN) Climb 136% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for FibroGen (FGEN) points to a 136% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
FibroGen (FGEN) Meets Main Goal in Chemo-Induced Anemia Study
by Zacks Equity Research
FibroGen (FGEN) announces positive top-line data from the study of its investigational candidate roxadustat, which is being evaluated to treat chemotherapy-induced anemia.
Fibrogen (FGEN)/Astellas Get EU Nod for Roxadustat for Anemia
by Zacks Equity Research
Roxadustat, FibroGen (FGEN) and Astellas' candidate for symptomatic anemia of chronic kidney disease, secures EU approval. The drug is to be sold in Europe under the brand name Evrenzo.
FibroGen's (FGEN) Drug for Anemia of CKD Gets CRL From FDA
by Zacks Equity Research
NDA for roxadustat, FibroGen's (FGEN) candidate for anemia of chronic kidney disease, fails to secure approval as the FDA requests additional clinical data on the drug. The stock declines resultantly.
FibroGen (FGEN) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
FibroGen (FGEN) delivered earnings and revenue surprises of -202.08% and -68.93%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Why FibroGen (FGEN) Might Surprise This Earnings Season
by Zacks Equity Research
FibroGen (FGEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
FibroGen (FGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
FibroGen (FGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FibroGen (FGEN) Roxadustat Fails to Win FDA Advisory Panel Vote
by Zacks Equity Research
FibroGen (FGEN) is seeking approval for roxadustat as potential treatment of anemia of chronic kidney disease in the United States. Stock down on unfavorable advisory committee outcome.
FibroGen (FGEN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
FibroGen (FGEN) delivered earnings and revenue surprises of 13.33% and 1.95%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for FibroGen (FGEN)
by Aditi Saraogi
FibroGen (FGEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Analysts Estimate FibroGen (FGEN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
FibroGen (FGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FibroGen (FGEN) DMD Drug Pamrevlumab Gets FDA's Fast Track Tag
by Zacks Equity Research
The FDA bestows a Fast Track designation to FibroGen's (FGEN) anti-CTGF antibody, pamrevlumab, to treat patients with Duchenne muscular dystrophy. Shares up.
Akebia (AKBA) Files NDA for Vadadustat for Anemia Due to CKD
by Zacks Equity Research
Akebia (AKBA) submits new drug application for vadadustat to treat anemia due to chronic kidney disease in adult patients who are on dialysis as well as who are not on dialysis.
FibroGen (FGEN) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
FibroGen (FGEN) delivered earnings and revenue surprises of -120.69% and -25.01%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
FibroGen (FGEN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
FibroGen (FGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FibroGen's (FGEN) Evrenzo Approved in Japan for Another Indication
by Zacks Equity Research
FibroGen's (FGEN) Evrenzo (roxadustat) wins second approval in Japan for treating anemia caused by chronic kidney disease in non-dialysis-dependent patients.
Find Strong Stocks with this First Profit Screener
by Benjamin Rains
Let's use our 'First Profit' screener to help find stocks that investors might want to consider buying after they posted positive earnings for the first time ever, or for some time...